Sino Biopharmaceutical Limited (01177.HK) Latest Company News

Oct 27, 2026, 08:12 UTC
Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.
Source:
- aastocks.com
Oct 27, 2026, 00:08 UTC
China's Center for Drug Evaluation included two innovative hepatitis B drugs developed by Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical Ltd., in its Breakthrough Therapy Designation program.
Source:
Oct 26, 2026, 12:45 UTC
The Sino Biopharmaceutical Ltd. reported that Pakistan’s call centre and BPO sector generated $101.315 million in foreign exchange receipts in the first quarter of fiscal year 2026–27, up 23.6% year over year.
Source:
- propakistani.pk
Oct 26, 2026, 00:04 UTC
Sino Biopharmaceutical Ltd. announced that two sets of clinical data for TQB2102 were presented at the 2026 ESMO Congress.
Source:
- finance.sina.cn
- aastocks.com
Oct 23, 2026, 01:55 UTC
China’s National Medical Products Administration approved Chia Tai Tianqing’s umeclidinium/vilanterol inhalation powder, marketed as Suxuan, for long-term maintenance treatment of chronic obstructive pulmonary disease.
Source:
- finance.sina.cn
Oct 22, 2026, 08:59 UTC
Sino Biopharmaceutical Ltd. repurchased 10 million shares at HK$4.955–HK$4.98 per share for approximately HK$49.778 million.
Source:
- aastocks.com
Oct 22, 2026, 04:12 UTC
Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.
Source:
Oct 20, 2026, 23:56 UTC
Sino Biopharmaceutical Ltd. completed enrollment of all participants in the Phase III registration trial of TQC2731 injection, a TSLP monoclonal antibody, for maintenance treatment of chronic rhinosinusitis with nasal polyps.
Source:
Oct 15, 2026, 01:44 UTC
Chia Tai Tianqing said its strategic-cooperation product Bepirovirsen was selected for two oral presentations and eight poster presentations at the 2026 AASLD annual meeting.
Source:
- aastocks.com
Oct 14, 2026, 09:23 UTC
Sino Biopharmaceutical Ltd. repurchased 8 million shares at HK$5.155–HK$5.175 per share for approximately HK$41.3232 million.
Source:
- aastocks.com
Oct 14, 2026, 08:12 UTC
Hong Kong-listed shares showed varied moves, led by gains in Meituan, Xiaomi and Alibaba and declines in several other active constituents; four stocks reached record highs.
Source:
- aastocks.com
Oct 13, 2026, 09:02 UTC
Sino Biopharmaceutical Ltd. repurchased 7.4 million shares at HK$5.325–HK$5.35 per share for approximately HK$39.5648 million.
Source:
- aastocks.com
Oct 9, 2026, 14:00 UTC
Pakistan Finance Minister Muhammad Aurangzeb met a Dutch business delegation to discuss trade and investment opportunities.
Source:
- paktribune.com
Oct 6, 2026, 08:12 UTC
Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.
Source:
Oct 3, 2026, 15:00 UTC
Pakistan's federal government amended the 2023 State-Owned Enterprises Ownership and Management Policy, requiring SOEs to follow IFRS accounting and internal audit procedures, under its IMF programme.
Source:
- samaa.tv
Sep 29, 2026, 08:11 UTC
Sinopharm subsidiary Chia Tai Tianqing signed a strategic biosimilar partnership with Germany's STADA, granting STADA exclusive rights to commercialize pembrolizumab biosimilar TQB3570 in the EU, Switzerland, the UK and the CIS, with an option to expand to the US and GCC markets.
Source:
- aastocks.com
Sep 28, 2026, 08:50 UTC
China Biopharmaceutical's subsidiary Chia Tai Tianqing signed a strategic partnership with STADA Arzneimittel AG to develop and commercialize biosimilars, granting STADA exclusive rights in the EU, Switzerland, the UK and the CIS.
Source:
- aastocks.com
Sep 21, 2026, 05:00 UTC
Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.
Source:
- cnbc.com
Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:
- aastocks.com
Sep 21, 2026, 02:17 UTC
Hong Kong stocks fell early then rebounded on Monday, with the Hang Seng Index dropping 13.86 points to 24,736.92 before rising over 145 points to 24,896.43, while biotech and pharmaceutical shares gained and Alibaba rose 2% and Alibaba Health fell 5%.
Source:
- aastocks.com
- aastocks.com
Sep 18, 2026, 04:30 UTC
China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.
Source:
- aastocks.com
- aastocks.com
Sep 18, 2026, 03:05 UTC
Sino Biopharmaceutical's management reiterated its full-year guidance for double-digit year-on-year revenue growth, driven by licensing income and innovative drug sales.
Source:
- aastocks.com
Sep 14, 2026, 08:12 UTC
Hong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.
Source:
- aastocks.com
- aastocks.com
Sep 11, 2026, 08:43 UTC
China Biologic Products Holdings (01177) agreed to acquire an additional 5% stake in Chia Tai Tianqing from its major shareholder for RMB 4.48 billion, raising its indirect holding from 60% to 65%.
Source:
Sep 8, 2026, 10:12 UTC
China Biologic Products' subsidiary Chia Tai Tianqing presented preclinical data for its oral STAT6 degrader TQH5528 at the European Respiratory Society 2026 congress (ERS 2026) via an oral presentation and electronic poster.
Source:
- aastocks.com
- aastocks.com
Aug 31, 2026, 10:14 UTC
CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody-drug conjugate TQB2102.
Source:
Aug 31, 2026, 00:03 UTC
China Biopharmaceuticals announced Phase I clinical data for its LPA siRNA drug Kylo-11 at the 2026 European Society of Cardiology Congress and in The Lancet.
Source:
- finance.sina.cn
- aastocks.com
Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:
- finance.sina.cn
Aug 21, 2026, 04:31 UTC
China Biologic Products (01177.HK) shares rose 3.62% to HK$5.585 in morning trading on August 21, 2026, following its earnings release.
Source:
- aastocks.com
Aug 20, 2026, 06:00 UTC
Chinese AI startup TranscEngram raised several hundred million yuan in an angel round from investors including SBP Group, PDVC, Zhangjiang Hi-Tech Park, and HON-Flex.
Source:
- nikkei.com
Aug 20, 2026, 04:01 UTC
China Biopharmaceutical (01177.HK) reported first-half 2026 results with net profit up 1.4% year-on-year to RMB 3.44 billion, significantly beating market and Citi expectations, and revenue up 10.6% to RMB 19.44 billion, driven by strong innovative drug sales growth of 44.3% to RMB 8.79 billion.
Source:
- aastocks.com

Page 1Next →

01177.HK

Hong Kong-listed shares showed mixed moves, including Xiaomi Corp. falling 4.6% and China Construction Bank, CK Infrastructure and H&H International Holdings reaching record highs.

China's Center for Drug Evaluation included two innovative hepatitis B drugs developed by Chia Tai Tianqing, a subsidiary of Sino Biopharmaceutical Ltd., in its Breakthrough Therapy Designation program.

The Sino Biopharmaceutical Ltd. reported that Pakistan’s call centre and BPO sector generated $101.315 million in foreign exchange receipts in the first quarter of fiscal year 2026–27, up 23.6% year over year.

Sino Biopharmaceutical Ltd. announced that two sets of clinical data for TQB2102 were presented at the 2026 ESMO Congress.

China’s National Medical Products Administration approved Chia Tai Tianqing’s umeclidinium/vilanterol inhalation powder, marketed as Suxuan, for long-term maintenance treatment of chronic obstructive pulmonary disease.

Sino Biopharmaceutical Ltd. repurchased 10 million shares at HK$4.955–HK$4.98 per share for approximately HK$49.778 million.

Hong Kong stocks fell at midday, with the Hang Seng Index down 679 points (2.9%) to 22,971, the Hang Seng Tech Index down 185 points (4.6%) to 3,809, and the Hang Seng China Enterprises Index down 248 points (3.1%) to 7,695.

Sino Biopharmaceutical Ltd. completed enrollment of all participants in the Phase III registration trial of TQC2731 injection, a TSLP monoclonal antibody, for maintenance treatment of chronic rhinosinusitis with nasal polyps.

Chia Tai Tianqing said its strategic-cooperation product Bepirovirsen was selected for two oral presentations and eight poster presentations at the 2026 AASLD annual meeting.

Sino Biopharmaceutical Ltd. repurchased 8 million shares at HK$5.155–HK$5.175 per share for approximately HK$41.3232 million.

Hong Kong-listed shares showed varied moves, led by gains in Meituan, Xiaomi and Alibaba and declines in several other active constituents; four stocks reached record highs.

Sino Biopharmaceutical Ltd. repurchased 7.4 million shares at HK$5.325–HK$5.35 per share for approximately HK$39.5648 million.

Pakistan Finance Minister Muhammad Aurangzeb met a Dutch business delegation to discuss trade and investment opportunities.

Hong Kong stocks closed higher on October 6, 2026, with the Hang Seng Index up 240 points (1.0%) at 24,280, the Hang Seng Tech Index up 39 points (0.9%) at 4,223, and the China Enterprises Index up 77 points (1.0%) at 8,128 on turnover of HK$98.265 billion.

Pakistan's federal government amended the 2023 State-Owned Enterprises Ownership and Management Policy, requiring SOEs to follow IFRS accounting and internal audit procedures, under its IMF programme.

Sinopharm subsidiary Chia Tai Tianqing signed a strategic biosimilar partnership with Germany's STADA, granting STADA exclusive rights to commercialize pembrolizumab biosimilar TQB3570 in the EU, Switzerland, the UK and the CIS, with an option to expand to the US and GCC markets.

China Biopharmaceutical's subsidiary Chia Tai Tianqing signed a strategic partnership with STADA Arzneimittel AG to develop and commercialize biosimilars, granting STADA exclusive rights in the EU, Switzerland, the UK and the CIS.

Chinese biopharma stocks jumped in Hong Kong on Monday, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up more than 6%, HUTCHMED up 3%, Sino Biopharmaceutical up 8%, and the Hang Seng Biotech Index up more than 5%.

Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.

Hong Kong stocks fell early then rebounded on Monday, with the Hang Seng Index dropping 13.86 points to 24,736.92 before rising over 145 points to 24,896.43, while biotech and pharmaceutical shares gained and Alibaba rose 2% and Alibaba Health fell 5%.

Sino Biopharmaceutical's management reiterated its full-year guidance for double-digit year-on-year revenue growth, driven by licensing income and innovative drug sales.

Hong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.

China Biologic Products Holdings (01177) agreed to acquire an additional 5% stake in Chia Tai Tianqing from its major shareholder for RMB 4.48 billion, raising its indirect holding from 60% to 65%.

China Biologic Products' subsidiary Chia Tai Tianqing presented preclinical data for its oral STAT6 degrader TQH5528 at the European Respiratory Society 2026 congress (ERS 2026) via an oral presentation and electronic poster.

CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody-drug conjugate TQB2102.

China Biopharmaceuticals announced Phase I clinical data for its LPA siRNA drug Kylo-11 at the 2026 European Society of Cardiology Congress and in The Lancet.

China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

China Biologic Products (01177.HK) shares rose 3.62% to HK$5.585 in morning trading on August 21, 2026, following its earnings release.

Chinese AI startup TranscEngram raised several hundred million yuan in an angel round from investors including SBP Group, PDVC, Zhangjiang Hi-Tech Park, and HON-Flex.

China Biopharmaceutical (01177.HK) reported first-half 2026 results with net profit up 1.4% year-on-year to RMB 3.44 billion, significantly beating market and Citi expectations, and revenue up 10.6% to RMB 19.44 billion, driven by strong innovative drug sales growth of 44.3% to RMB 8.79 billion.